Sangamo BioSciences | SGMO - Операционный доход





Операционный доход Изменить Дата
Alaunos Therapeutics USD -1.19M 148K 2025-09
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
Alterity Therapeutics Limited AUD -7.77M 2.99M 2023-06
Amgen USD 3.96B 464M 2025-12
Bayer EUR 1.11B 1.65B 2025-12
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Biogen USD 659.6M 192.2M 2025-09
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Cipla INR 9.77B 6.21B 2025-12
Clal Biotechnology ILS -1.74M 7.46M 2022-12
Compugen USD 56.04M 63.93M 2025-12
CSL USD 2.64B 1.97B 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Grifols EUR 320.55M 91.01M 2025-12
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
J&J USD 5.59B 1.81B 2025-12
Karyopharm Therapeutics USD -31.28M 5M 2024-12
Merck USD 6.24B 318M 2025-12
Novartis USD 4.06B 437M 2025-12
Omeros USD -35.41M 23.75M 2024-09
Pfizer USD 4.65B 3.99B 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sanofi EUR 1.7B 2.17B 2025-12
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
Tectonic Therapeutic USD -21.52M 374K 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12